Pharmaceutical Non-Active Ingredients TRIZ Cases

Direct copolymerization yields defined structures that prevent premature leakage, resolving synthesis complexity while maintaining stability.

Combines a PARP inhibitor with a long-acting topoisomerase I inhibitor to target cancer cells through multiple pathways simultaneously.

Styrene-modified elastomeric compounds maintain physical properties during gamma irradiation, preventing deterioration of pharmaceutical stoppers.

Antioxidants and pH modifiers suppress nitrosamine formation to meet FDA limits.

Segmenting active substances prevents incompatibility while disintegrants ensure rapid dissolution.

Comparing interfacial tension decreases identifies lubricant interactions to prevent protein degradation in prefilled injection devices.

A synthetic copolymer conjugate carries affinity tags, imaging probes, and targeting ligands to bind proteins.

A film coating composition uses polyvinyl alcohol with a specific hydrolysis degree to reduce tablet stickiness during the coating process.

Segmented organic solvent injection and dynamic stirring enable scalable production of homogeneous adjuvant formulations with consistent particle size.

Zwitterion polymer conjugates link therapeutic polypeptides to inhibit aggregation, maintaining efficacy while avoiding toxicity from protein clumping.

Segmented PBD conjugates exploit differential folate receptor expression to selectively deliver toxins, reducing host toxicity.

Dry-heat amorphization de-clusters starch before ultrasonic complexing with amino acids to form VI-type crystals.

Cyclooctyne click chemistry attaches payloads to antibodies, resolving heterogeneous drug loading and off-target toxicities.

Cyclodextrin coatings on charged cores coordinate drug release kinetics to resolve pharmacokinetic mismatches and non-specific tissue accumulation.

Oxyma and DIC coupling agents synthesize hyaluronan-drug conjugates in a homogeneous DMSO reaction phase.

Carbamate linkages in polymeric reagents enable customizable hydrolysis rates, extending drug half-life while reducing immunogenicity.

Segmented antibodies targeting distinct CD3 chains improve treatment efficacy for TCR-CD3 diseases while minimizing off-target effects.

Rotary moulding machines produce uniform soft chews weighing 2g or less, resolving size and weight inconsistencies of conventional pressure systems.

Conjugates retain effector function by binding to Fc-gamma receptors, resolving the trade-off between targeted delivery and immune cell activation.

Hyaluronic acid grafted with dextran tyramine uses enzymatic crosslinking to resolve slow gelation and cytotoxicity from photo-initiators.

A segmented adhesive matrix stabilizes a supersaturated active agent, preventing precipitation while maintaining high drug permeation rates across the skin.

Oxybate-polyethylene glycol ester prodrugs extend plasma detection via controlled hydrolysis, reducing toxicity and abuse potential in narcolepsy treatment.

Antibody medicant conjugates deliver cytotoxic payloads via selective receptor binding, resolving systemic toxicity trade-offs in solid tumor treatment.

Prevents crystallization of slightly water-soluble active substances by maintaining molecular dispersion in composite polymer matrices.

Methylene carbamate linkers resolve high pKa instability in aliphatic alcohol drugs, ensuring controlled release and reduced toxicity.

Cell-penetrating peptide mediated delivery of PEG-conjugated ASOs via pacDNA reduces systemic toxicity while maintaining effective KRAS inhibition.

Integrating monovalent metal ions into gellan gum shells resolves the trade-off between mechanical strength and water disintegrability, simplifying production.

A conjugation method uses a thiol generator in simultaneous contact with chemical entities to form covalent bonds without intermediate separation steps.

Supramolecular assemblies enable targeted and controlled release of therapeutic agents through micellular structures.

Ketone-functionalized polymers replace aldehydes to resolve imprecise conjugation, reducing immunogenicity and improving pharmacokinetic profiles.

Fractional elution separates polymer vectors into narrow molecular weight distributions, resolving reproducibility issues in gene therapy.

Segmenting carbohydrate delivery across distinct molecular forms increases absorption capacity while preventing gastrointestinal distress.

Replacing gelatin with agar and starch eliminates animal-derived ingredients while preventing cracking during storage.

Multi-arm polymer prodrugs attach active agents to water-soluble backbones via hydrolyzable linkages, reducing clearance rates and side effects.

A pHLIP liposome conjugates peptides to polar headgroups for targeted cargo delivery into acidic tissue environments.

Covalent TLR7-TLR2 conjugates overcome tumor niche barriers by leveraging polycationic properties for endosomal delivery and robust immune activation.

Functionalized exosomes deliver molecular cargo via covalent bonds, resolving toxicity and loading efficiency trade-offs.

TM1 taste modulator reduces bitter taste perception in foods, beverages, and pharmaceuticals without adding sugar.

Volatile base vaporization drops pH to release multivalent ions, enabling uniform microcapsule production via spray drying.

Encapsulating Fluorocoxib A in ROS-responsive nanoparticles overcomes solubility barriers and prevents rapid renal clearance.

A method creates nanoscale emulsions using oppositely charged surfactants to overcome interfacial repulsions and induce droplet fusion.

Combination therapy using 6,8-bis(benzylsulfanyl)octanoic acid with gemcitabine and nab-paclitaxel targets pancreatic cancer cells effectively.

A cannabinoid-chemotherapy complex crosses the blood-brain barrier to deliver targeted cancer treatment.

Phosphonium ionic conjugates improve drug solubility and membrane penetration to overcome poor bioavailability and blood-brain barrier limitations.

Segmented polyethylene oxide fractions resolve manufacturing stickiness while maintaining sustained drug release and content uniformity.

Engineered IgG hinge cysteine residues enable site-specific drug conjugation for homogeneous antibody-drug conjugates.

Nerve delivery molecules incorporate D-amino acids and cyclic linkers to extend plasma half-life and reduce non-specific uptake in non-target tissues.